Skip to main content
Premium Trial:

Request an Annual Quote

Decode s Revenues Drop 8 Percent, Losses Widen in Q1

NEW YORK, May 3 (GenomeWeb News) - Decode Genetics yesterday reported an 8-percent drop in revenues and a widened net loss for the first quarter of 2005.


Revenues for the quarter totaled $9.5 million, down from $10.3 million for the same period a year ago. This decrease reflects the company's new focus on drug discovery and development, according to Decode. The company said it also had $17.5 million in deferred research revenue on March 31, which it will recognize in future quarters.


Research and development costs almost doubled to $8.3 million from $4.3 milion during last year's first quarter. This increase results mainly from the cost of clinical trials of Decode's drug-development programs.


Decode's net loss widened to $16.9 million from $12 million during the year-ago quarter.


As of March 31, Decode had $197.6 million in cash, cash equivalents, and investments, including restricted cash.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.